Pharvaris (NASDAQ:PHVS) Hits New 12-Month High – What’s Next?

Shares of Pharvaris N.V. (NASDAQ:PHVS) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $36.93 and last traded at $36.59, with a volume of 22959 shares trading hands. The stock had previously closed at $36.39.

Analyst Ratings Changes

A number of research firms have recently commented on PHVS. Morgan Stanley lifted their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research note on Thursday, June 25th. Citizens Jmp increased their target price on Pharvaris from $74.00 to $75.00 and gave the company a “market outperform” rating in a research note on Thursday, August 13th. Guggenheim raised their target price on Pharvaris from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, August 13th. UBS Group set a $74.00 price target on Pharvaris in a research report on Wednesday, May 13th. Finally, New Street Research set a $60.00 price target on Pharvaris in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.08.

Pharvaris Price Performance

The firm has a market cap of $2.40 billion, a P/E ratio of -12.03 and a beta of -2.31. The company’s 50 day moving average is $34.06 and its two-hundred day moving average is $30.35.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Research analysts predict that Pharvaris N.V. will post -3.15 EPS for the current year.

Insider Buying and Selling at Pharvaris

In related news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the sale, the director owned 315,167 shares of the company’s stock, valued at $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Anne Lesage sold 30,703 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the sale, the insider directly owned 93,969 shares in the company, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 121,325 shares of company stock valued at $4,270,425 in the last 90 days. Insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

Several institutional investors have recently bought and sold shares of PHVS. venBio Partners LLC acquired a new position in Pharvaris during the second quarter worth $160,569,809,000. Deerfield Management Company L.P. increased its holdings in shares of Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after buying an additional 425,000 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after acquiring an additional 274,034 shares during the last quarter. Commodore Capital LP raised its stake in shares of Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after acquiring an additional 29,525 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP boosted its holdings in shares of Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.